Biotechnology is often a story of patience, rigorous science, and the relentless pursuit of life-changing therapies. Nowhere is this more evident than in the field of gene therapy, especially concerning devastating conditions like Duchenne Muscular Dystrophy (DMD). Regenxbio, Inc. (NASDAQ: RGNX) has recently provided a significant update, illuminating a clear roadmap toward crucial 2026 catalysts…